Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Ranibizumab in Diabetic Macular Edema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Visual acuity impairment caused by macular edema in at least one eye~* Type 1 or type 2 diabetes mellitus~* Stable medication of diabetes in past 3 month~Exclusion Criteria:~* Patients with uncontrolled systemic or ocular diseases~* Laser photocoagulation in the study eye for the last 3 months~* Any history of any intraocular surgery in the study eye within the past 3 months~* Blood pressure \> 160/100 mmHg~Other protocol defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active laser photocoagulation and ranibizumab (Type: EXPERIMENTAL): Active laser treatment applied at baseline and reapplied if needed at intervals no shorter than 3 months from the last treatment.~Ranibizumab intravitreal injection given at baseline, at 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment.
- Active laser photocoagulation and sham injection (Type: ACTIVE_COMPARATOR): Active laser treatment applied at baseline and reapplied if needed at intervals no shorter than 3 months from the last treatment.~Sham intravitreal injection given at baseline, at 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).